Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg to market a generic equivalent of Lyrica® Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg of Upjohn US 2 LLC. The product will be manufactured at Lupin's facility in Aurangabad, India.
Pregabalin Capsules (RLD Lyrica®) had estimated annual sales of USD 263 million in the U.S. (IQVIA MAT March 2022).
Shares of Lupin Limited was last trading in BSE at Rs. 726.25 as compared to the previous close of Rs. 726.50. The total number of shares traded during the day was 22613 in over 1317 trades.
The stock hit an intraday high of Rs. 744.10 and intraday low of 724.75. The net turnover during the day was Rs. 16582849.00.